MedTrace Logo

Prophylaxis Against Post-Endoscopic Retrograde Cholangio-Pancreatography Pancreatitis.

NCT07599605 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-20

No results posted yet for this study

Summary

Endoscopic retrograde cholangiopancreatography (ERCP) is a key procedure for managing biliopancreatic diseases, although it is associated with complications such as post-ERCP pancreatitis. This study assessed the efficacy of a prophylactic protocol combining rectal indomethacin with aggressive hydration to reduce the incidence of post-ERCP pancreatitis and serum amylase and lipase levels.

Conditions

Interventions

DRUG

Rectal Indometacin

The gold standard for treating diseases affecting the biliopancreatic ducts, choledocholithiasis being the most common indication, for which sphincterotomy is the most frequently performed procedure.

Sponsors & Collaborators

  • Hospital General de Chihuahua - Dr. Salvador Zubirán Anchondo

    lead OTHER_GOV

Principal Investigators

  • Rubén Cuevas-Martínez, MD, MSc · Chihuahua City General Hospital "Dr. Salvador Zubirán Anchondo"

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-04
Primary Completion
2024-12-27
Completion
2025-01-17
FDA Drug
Yes

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07599605 on ClinicalTrials.gov